High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
Open Access
- 29 September 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in Cancer Biology & Therapy
- Vol. 23 (1), 1-6
- https://doi.org/10.1080/15384047.2022.2128608
Abstract
Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications – “amplificators”. We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.Keywords
Funding Information
- National Cancer Institute (P30 CA023100)
This publication has 23 references indexed in Scilit:
- TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsMolecular Cancer Therapeutics, 2016
- Pan-cancer analysis of the extent and consequences of intratumor heterogeneityNature Medicine, 2015
- Gene amplification: mechanisms and involvement in cancerBioMolecular Concepts, 2013
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Gene amplification in cancerTrends in Genetics, 2006
- Gene Amplification MechanismsPublished by Springer Science and Business Media LLC ,2005
- Regulation and mechanisms of gene amplificationPhilosophical Transactions B, 1995
- Database of p53 gene somatic mutations in human tumors and cell lines.1994
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989